Jefferies Starts Pardes Biosciences (PRDS) at Buy

Jefferies analyst Dennis Ding initiates coverage on Pardes Biosciences (NASDAQ: PRDS) with a Buy rating and a price target of $25.00.

The analyst commented, "Convenient oral pills to broadly treat COVID will drive the world towards an endemic phase and unlock economic recovery since new variants have reduced efficacy from antibodies and vaccines. PRDS has a potent antiviral pill targeting SARS-CoV-2 regardless of variant and has already been partially derisked by competitor PFE with strong efficacy. PRDS is starting pivotal by mid-2022 with many catalysts over next 6-18 months yet only $1B market cap. "

For an analyst ratings summary and ratings history on Pardes Biosciences click here. For more ratings news on Pardes Biosciences click here.

Shares of Pardes Biosciences closed at $13.95 yesterday.

You May Also Be Interested In

• Morgan Stanley Starts Rocket Pharmaceuticals (RCKT) at Overweight, Sees Over 100% Upside
• JPMorgan Downgrades Grab Holdings Inc. (GRAB) to Underweight, 'Recommend tactical UW on risk of earnings missing expectations'
• Several positive 2023 catalysts can boost TransUnion (TRU) valuation - BofA